Nektar Therapeutics (NKTR)
$37.92-4.82%Close
SELLCRISIS · day 16
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $741M
- Beta
- 1.15
- P/E (TTM)
- -5.66
- Short % float
- 38.02%
- Days to cover
- 3.8
- SI change
- +21.5%
- 1W
- -4.99%
- 1M
- -44.64%
- vs SPY 1W
- -4.85%
- vs SPY 1M
- -47.15%
Industry peers
FMP comparable companies · ranked by market cap
- RCUSSELLArcus Biosciences, Inc.$3.1BCRISISQ 17$24.28-7.52%
- XNCRSELLXencor, Inc.$1.8BRECOVERYQ 15$24.36-6.07%
- IMCRSELLImmunocore Holdings plc$1.5BBEARQ 1$29.55-4.20%
- IMTXSELLImmatics N.V.$1.0BCRISISQ 5$7.50-5.27%
- CRVSSELLCorvus Pharmaceuticals, Inc.$888MCRISISQ 12$10.56-6.37%
- ANLSELLAdlai Nortye Ltd.$768MCRISISQ 10$14.46-17.30%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
ANALYST & RATINGS
LOADING…Loading analyst data…
Company news
FAQ
- What is LOPJLB’s current signal on NKTR?
- LOPJLB’s latest quantitative signal on Nektar Therapeutics (NKTR) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is NKTR in?
- Nektar Therapeutics (NKTR) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Nektar Therapeutics (NKTR) do?
- Nektar Therapeutics is a biopharmaceutical firm dedicated to the global discovery and advancement of therapies addressing significant unmet medical requirements. Central to its robust pipeline is Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist. This drug is currently in Phase 3 clinical trials for metastatic melanoma, renal cell carcinoma, muscle-invasive bladder ca…